MassDevice Q&A: Amar Sawhney

June 19, 2009 by Brian Johnson

The founder of six companies, including Waltham's I-Therapeutix, on market conditions and the future of medical devices.

Amar Sawhney has a knack for turning gel into gold.

Over the years, the serial entrepreneur managed to leverage his work in hydrogel technology at the University of Texas into the basis for six companies, including one snapped up by Genzyme early in the decade and another that Covidien predecessor Tyco Healthcare acquired in 2006.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

Animal rights advocacy group PETA holds a tiny stake in several medtech companies, taking frequent advantage of its shareholder rights to push changes in the way device makers experiment on animals.

AliveCor's interim-ish CEO Euan Thomson talks about the data-driven future, why he jumped ship at Accuray and how to navigate the intersection between the tempered medical device world and the wanton nimbleness of Silicon Valley.

Medtronic executive Dr. Stephen Oesterle thinks Google will be a force to be reckoned with in the medical technology space in coming years.

Roger Pontz, 1 of the first recipients of Second Sight Medical's Argus II 'bionic eye,' tells MassDevice.com about how it's changed his life.

Definiens CEO Thomas Heydler discusses his ambition to position his company at the forefront of the coming revolution in personalized and predictive medicines.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp